Intrepid Acts as Exclusive Financial Advisor to Ambry Genetics on its Sale to Konica Minolta in a Deal Valued at US$1 Billion
2017年10月25日 - 10:00PM
ビジネスワイヤ(英語)
Acquisition secures a leading position for Konica Minolta in
precision medicine and introduces the world’s most comprehensive
genetic-diagnostic solutions to Japan, Europe, and other
markets
Intrepid Investment Bankers (Intrepid), a leading middle-market
investment bank, today announced that it acted as the exclusive
financial advisor to U.S.-based Ambry Genetics Corporation (Ambry)
on its sale to Konica Minolta (TSE:4902)—a global digital
technology company with core strengths in imaging and data
analysis, optics, materials, and nano-fabrication.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171025005406/en/
Intrepid served as the exclusive
financial advisor to Ambry Genetics Corporation. (Graphic: Business
Wire)
Konica Minolta, through its subsidiary Konica Minolta Healthcare
Americas, Inc. (MHUS), and Innovation Network Corporation of Japan
(INCJ) made a closing payment of $800 million to Ambry’s
shareholders. Over the next two years, Ambry shareholders will
receive up to $200 million in incremental consideration based on
certain financial metrics, valuing the acquisition up to a total of
US$1 billion. Ambry will become a consolidated subsidiary of Konica
Minolta and continue to operate at its headquarters in Aliso Viejo,
Calif., and under the Ambry name.
“Konica Minolta is the type of strategic partner we have been
searching for—Intrepid’s Healthcare team was creative and
thoughtful in bringing us a range of outstanding partner choices,
from financial institutions interested in our space, to major
players in healthcare. Ultimately, we felt that Konica Minolta was
by far the best partner to help us take our strategic vision of
helping humanity cure disease much closer to reality,” said Charles
Dunlop, Founder, President, and Chairman of Ambry Genetics.
“Intrepid understood our culture and history of innovation, and
through the Konica Minolta partnership, we will have the resources,
technology, and scale to advance biomedical research and enable the
matching of more patients in more countries with specialized
medicines that target the underlying cause of their illness,” added
Dr. Aaron Elliott, CEO of Ambry Genetics.
“Ambry is a special company that received major interest from
strategics and institutional investors. Charlie Dunlop built a
unique culture on a simple imperative: use genetics to diagnose
disease early to save lives. Charlie is a force of nature—his
vision built an industry leader that is now well positioned with an
exceptional partner to fulfill its promise,” said Ed Bagdasarian,
Chief Executive Officer and Managing Director of Intrepid.
As an emerging player in the healthcare field, Konica Minolta
has developed comprehensive technologies and services, including
digital X-ray diagnostic imaging systems, diagnostic ultrasound
systems, and ICT service platforms for medical institutions. “This
acquisition is the first in a series of strategic initiatives to
secure a leading position for Konica Minolta in precision
medicine,” said Shoei Yamana, President and CEO of Konica Minolta.
“The future of medicine is patient-focused. Together with Ambry, we
will have the most comprehensive set of diagnostic technologies for
mapping an individual’s genetic and biochemical makeup, as well as
the capabilities to translate that knowledge into information the
medical community can use to discover, prevent, and
cost-effectively treat diseases. This will not only serve as the
future foundation for our healthcare business but it will pave the
way for a fundamental shift in the way medicine is practiced
globally.”
About Ambry Genetics
Founded in 1999, Ambry Genetics is a privately-held healthcare
company in the U.S., led by Founder, President, and Chairman
Charles L.M. Dunlop and CEO Dr. Aaron Elliott. Ambry is known as a
pioneer and thought leader in genetic testing and is the first
laboratory in the world to offer such tests as hereditary cancer
panels and clinical exome sequencing. Ambry’s mission has remained
focused on understanding disease so cures can come faster. Today,
Ambry remains unwavering in its commitment to being tough,
innovative, committed to quality, and, most of all, focused to do
what is right for patient care.
About Konica Minolta
Konica Minolta, Inc. is a global digital technology company with
core strengths in imaging and data analysis, optics, materials, and
nano-fabrication. Through innovation, the company creates products
and digital solutions for the betterment of business and
society—today and for generations to come. Headquartered in Tokyo
and with operations in more than 50 countries, Konica Minolta has
more than 43,000 employees serving approximately two million
customers in over 150 countries. Konica Minolta is listed on the
Tokyo Stock Exchange (TSE:4902).
Deal Team Contacts
Ed Bagdasarian, CEO and Managing DirectorSteve Davis, Managing
DirectorAdam Abramowitz, Managing DirectorJonathan Bluth, Senior
Vice President and Head of Healthcare
About Intrepid Investment Bankers
Intrepid provides M&A, capital raising and strategic
advisory services to entrepreneurs and middle-market
companies in various industry sectors. Our heritage,
rooted in our founders’ successful 35-year history, breeds a
culture that embraces teamwork, tenacity, and creativity to win big
for our clients. We believe that every company has an
entrepreneurial passion that drives it and a story that defines
it. Our team delivers results through skillful
positioning and relentless execution. Based in Los Angeles,
Intrepid augments its international capabilities through its active
participation in Oaklins, an exclusive global alliance of
M&A advisory firms.
Intrepid homepageLinkedInFacebookTwitter
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171025005406/en/
Intrepid Investment BankersAndreea Popa, 310-478-9000 ext.
219Director, Marketing & Communicationsapopa@intrepidib.com